Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 · New England Journal of Medicine · 12K citations
https://doi.org/10.1056/nejmoa1504720
C
Christoph Wanner
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.3K
Papers
100.6K
Citations
135
h-index
680
i10-index
Christoph Wanner is an academic researcher from Universitätsklinikum Würzburg. The author has contributed to research in topics: Diabetes Treatment and Management & Dialysis and Renal Disease Management & Chronic Kidney Disease and Diabetes. The author has an h-index of 135, co-authored 1103 publications.
ORCID: 0000-0001-9507-5301Papers by this author
works2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
2021 · European Heart Journal · 5,787 citations
https://doi.org/10.1093/eurheartj/ehab484
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
2021 · European Heart Journal · 5,787 citations
https://doi.org/10.1093/eurheartj/ehab484
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 · New England Journal of Medicine · 3,565 citations
https://doi.org/10.1056/nejmoa1515920
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
2023 · Journal of Hypertension · 2,831 citations
https://doi.org/10.1097/hjh.0000000000003480
A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease
2007 · Kidney International · 1,912 citations
https://doi.org/10.1038/sj.ki.5002585
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat